Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1332-1334

  Rae, James M ^a   Regan, Meredith M ^b   Thibert, Jacklyn N ^b   Gersch, Christina ^b   Thomas, Dafydd ^b   Leyland Jones, Brian ^b   Viale, Giuseppe ^b   Pusztai, Lajos ^b   Hayes, Daniel F ^b   Skaar, Todd ^b   Van Poznak, Catherine ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ARTICLE; BLOOD CELL; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FORMALIN FIXED PARAFFIN EMBEDDED TUMOR; FORMALIN FIXED PARAFFIN EMBEDDED UNAFFECTED LYMPH NODE; GENE AMPLIFICATION; GENE MAPPING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD CELLS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DNA, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENOTYPE; HUMANS; LYMPH NODES; TAMOXIFEN;

EID: 84884494450     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt204     Document Type: Article

References (22)

1. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446- 1452.
2. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
3. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.
4. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
5. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
6. Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489-500.
7. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441-451.
8. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
9. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758-1764.
10. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61-74.
11. Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist. 2012;17(5):620-630.
12. Pharoah PD, Abraham J, Caldas C. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(16):1263-1264.
13. Stanton V Jr. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1265-1266.
14. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1264.
15. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics. 2003;13(8):501-507.
16. Ramamoorthy A, Flockhart DA, Hosono N, Kubo M, Nakamura Y, Skaar TC. Differential quantification of CYP2D6 gene copy number by four different quantitative realtime PCR assays. Pharmacogenet Genomics. 2010;20(7):451-454.
17. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229-243.
18. Ahern TP, Christensen M, Cronin-Fenton DP, et al. Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol. 2010;2(22):241-246.
19. Benetkiewicz M, Piotrowski A, Díaz De Ståhl T, et al. Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol. 2006;29(4):935-945.
20. Hirano A, Emi M, Tsuneizumi M, et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res. 2001;7(4):876-882.
21. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70
22. Ellis MJ, Ding L, Shen D, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-360.